Carprodolor 50 mg/ml Solution for Injection for Cattle

Main information

  • Trade name:
  • Carprodolor 50 mg/ml Solution for Injection for Cattle
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Carprodolor 50 mg/ml Solution for Injection for Cattle
    Spain
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • carprofen
  • Therapeutic area:
  • Cattle

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0429/001
  • Authorization date:
  • 23-01-2013
  • EU code:
  • UK/V/0429/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:May2013

AN:01920/2011

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Carprodolor50mg/mlsolutionforinjectionforcattle

Carprodolorvet.50mg/mlsolutionforinjectionforcattle(FI)

Carprosan50mg/mlsolutionforinjectionforcattle(ES,PT)

Carprosanvet.50mg/mlsolutionforinjectionforcattle(NO,SE,DK,IS)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Perml:

Activesubstance:

Carprofen 50mg

Excipient(s):

Ethanol96% 0.1ml

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

SolutionforInjection

Clearpalestrawcolouredliquid

4. CLINICALPARTICULARS

4.1Targetspecies

Cattle

4.2Indicationsforuse,specifyingthetargetspecies

Theproductisindicatedasanadjuncttoantimicrobialtherapytoreduceclinical

signsinacuteinfectiousrespiratorydiseaseandacutemastitisincattle.

4.3Contraindications

Donotuseinanimalssufferingfromcardiac,hepaticorrenalimpairment.

Donotuseinanimalssufferingfromgastro-intestinalulcerationorbleeding.

Donotusewherethereisevidenceofablooddyscrasia.

Donotuseincasesofhypersensitivitytotheactivesubstanceortoanyofthe

excipients.

Issued:May2013

AN:01920/2011

Page2of6

4.4Specialwarnings

None

4.5Specialprecautionsforuse

i. Specialprecautionsforuseinanimals

Avoiduseinanydehydrated,hypovolaemicorhypotensiveanimal,asthere

isapotentialriskofincreasedrenaltoxicity.Concurrentadministrationof

potentiallynephrotoxicdrugsshouldbeavoided.

Donotexceedthestateddoseorthedurationoftreatment.

DonotadministerotherNSAID’sconcurrentlyorwithin24hoursofeach

other.

AsNSAIDtherapycanbeaccompaniedbyGIorrenalimpairment,

adjunctivefluidtherapyshouldbeconsideredespeciallyinthecaseofacute

mastitistreatment.

ii. Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Carprofen,incommonwithotherNSAIDs,hasbeenshowntoexhibit

photosensitisingpotentialinlaboratorystudies.Avoidskincontactwiththe

veterinarymedicinalproduct.Shouldthisoccur,washtheaffectedareas

immediately.

Takecaretoavoidaccidentalself-injection.Intheeventofaccidentalself-

injectionseekmedicaladviceimmediately.

4.6Adversereactions(frequencyandseriousness)

Studiesincattlehaveshownthatatransientlocalreactionmayformatthesiteof

theinjection.

4.7Useduringpregnancy,lactationorlay

Intheabsenceofanyspecificstudiesinpregnantcattle,useonlyaftera

risk/benefitassessmenthasbeenperformedbytheattendingveterinarysurgeon.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Nospecificsignificantdruginteractionshavebeenreportedforcarprofen.During

clinicalstudiesincattlefourdifferentantibioticclasseswereused,macrolides,

tetracyclines,cephalosporinsandpotentiatedpenicllinswithoutknown

interactions.However,incommonwithotherNSAIDs,carprofenshouldnotbe

administeredsimultaneouslywithanotherveterinarymedicinalproductofthe

Issued:May2013

AN:01920/2011

Page3of6

NSAIDorglucocorticoidclass.Animalsshouldbecarefullymonitoredifcarprofen

isadministeredsimultaneouslywithananticoagulant.

NSAID’sarehighlyboundtoplasmaproteinsandmaycompetewithotherhighly

bounddrugs,suchthatconcomitantadministrationmayresultintoxiceffects.

4.9Amountstobeadministeredandadministrationroute

Singlesubcutaneousorintravenousinjectionatadosageof1.4mgcarprofen/kg

bodyweight(1ml/35kg)incombinationwithantibiotictherapy,asappropriate.

Thestoppershouldnotbepuncturedmorethan20times.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Inclinicalstudies,noadversesignswerereportedafterintravenousand

subcutaneousadministrationofupto5timestherecommendeddose.

Thereisnospecificantidoteforcarprofenoverdosagebutgeneralsupportive

therapy,asappliedtoclinicaloverdosagewithNSAID’s,shouldbeapplied.

4.11Withdrawalperiod(s)

Meatandoffal:21days

Milk: Zerohours

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Anti-inflammatoryandAnti-rheumaticproducts,

non-steroids

ATCvetcode:QM01AE91

5.1Pharmacodynamicproperties

Carprofenisamemberofthe2-arylpropionicacidgroupofnon-steroidalanti-

inflammatorydrugs(NSAID’s),andpossessesanti-inflammatory,analgesicand

antipyreticactivity.

Carprofen,likemostotherNSAID’sisaninhibitoroftheenzymecyclo-oxygenase

ofthearachidonicacidcascade.However,theinhibitionofprostaglandin

synthesisbycarprofenisslightinrelationtoitsanti-inflammatoryandanalgesic

potency.Theprecisemodeofactionisunclear.

Studieshaveshownthatcarprofenhaspotentantipyreticactivityandsignificantly

reducestheinflammatoryresponseinlungtissueincasesofacute,pyrexic

infectiousrespiratorydiseaseincattle.Studiesincattlewithexperimentally

inducedacutemastitishaveshownthatcarprofenadministeredintravenouslyhas

potentantipyreticactivityandimprovesheartrateandrumenfunction.

Issued:May2013

AN:01920/2011

Page4of6

5.2Pharmacokineticparticulars

Absorption:Followingasinglesubcutaneousdoseof1.4mgcarprofen/kgthe

maximumplasmaconcentration(C

)of15.4μg/mlwasreachedafter(T

)7-19

hours.

Distribution:Thehighestcarprofenconcentrationsarefoundinbileandplasma

andmorethan98%ofcarprofenisboundtoplasmaproteins.Carprofenwaswell

distributedinthetissueswiththehighestconcentrationsfoundinkidneyandliver

followedbyfatandmuscle.

Metabolism:Carprofen(parent)isthemaincomponentinalltissues.Carprofen

(parentcompound)isslowlymetabolisedprimarilybyringhydroxylation,

hydroxylationattheα-carbonandbyconjugationofthecarboxylicacidgroupwith

glucuronicacid.The8-hydroxylatedmetaboliteandunmetabolizedcarprofen

predominateinthefaeces.Bilesamplesarecomprisedofconjugatedcarprofen.

Elimination:Carprofenhasaplasmaeliminationhalf-lifeof70hours.Carprofenis

primarilyexcretedinthefaeces,indicatingthatthebiliarysecretionplaysan

importantrole.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Ethanol96%

Macrogol400

Poloxamer188

Ethanolamine

Waterforinjection

6.2Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnot

bemixedwithotherveterinarymedicinalproducts.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days

6.4.Specialprecautionsforstorage

Donotrefrigerateorfreeze

Keepthevialintheoutercartoninordertoprotectfromlight.

6.5Natureandcompositionofimmediatepackaging

Issued:May2013

AN:01920/2011

Page5of6

50mlamberglass(TypeI)vialscappedwithchlorbutylrubberstopperretainedby

analuminiumcrimpedsealinacardboardbox.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements

7. MARKETINGAUTHORISATIONHOLDER

LeVetBeheerB.V.

Wilgenweg7

3421TVOudewater

TheNetherlands

8. MARKETINGAUTHORISATIONNUMBER

Vm41821/4002

9. DATEOFFIRSTAUTHORISATION

May2013

10.DATEOFREVISIONOFTHETEXT

May2013

Issued:May2013

AN:01920/2011

Page6of6

APPROVED 7/05/13

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

19-11-2018

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

One lot each of Option Family Sunscreen Lotion SPF 50 and Personnelle Sport Sunscreen Lotion SPF 50 have been voluntarily recalled by Empack Spraytech Inc. because of bacterial contamination.

Health Canada

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

17-7-2018

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

FDA - U.S. Food and Drug Administration

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration